Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 4/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5399 | 1.00 | TDP1 (0.59) | TDP1GRM5HTTCYP11B1CYP11B2 | |
| SCHEMBL28652434 | 0.98 | TDP1 (0.57) | TDP1GRM5HTTCYP11B1CYP11B2 | |
| Bromide SCHEMBL10432264 | 0.98 | TDP1 (0.57) | TDP1GRM5HTTCYP11B1CYP11B2 | |
| Bromide SCHEMBL6955674 | 0.98 | TDP1 (0.57) | TDP1GRM5HTTCYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL7206595 | 0.98 | TDP1 (0.57) | TDP1GRM5HTTCYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL3713895 | 0.98 | TDP1 (0.57) | TDP1GRM5HTTCYP11B1CYP11B2 | |
| Iodide SCHEMBL15375366 | 0.98 | TDP1 (0.57) | TDP1GRM5HTTCYP11B1CYP11B2 | |
| Methylamine SCHEMBL28557648 | 0.96 | TDP1 (0.55) | TDP1GRM5HTTCYP11B1CYP11B2 | |
| SCHEMBL30395666 | 0.92 | TDP1 (0.52) | TDP1GRM5HTTCYP11B1CYP11B2 | |
| SCHEMBL15639423 | 0.92 | TDP1 (0.52) | TDP1GRM5HTTCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | BREYE THERAPEUTICS APS (DK) | 2026-02-10 | — | — | US | claimed |
| EP-4655285-A1 | CALIX[4]ARENES WITH HIGH ANTICANCER ACTIVITY | Université Grenoble Alpes (FR) | 2025-12-03 | — | — | EP | claimed |
| WO-2025149628-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF NICOTINAMIDE N-METHYL TRANSFERASE | ASTRAZENECA AB (SE) | 2025-07-17 | — | — | WO | claimed |
| CN-119978002-A | Mononuclear zinc complex and preparation method and application thereof | 广西师范大学 | 2025-05-13 | — | — | CN | claimed |
| WO-2025049402-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | claimed |
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-02-13 | — | — | US | claimed |
| EP-4441275-A1 | METHOD FOR THE ELECTRO-OXIDATION OF A FURAN COMPOUND | IFP Energies nouvelles (FR) | 2024-10-09 | — | — | EP | claimed |
| WO-2024156819-A1 | CALIX[4]ARENES WITH HIGH ANTICANCER ACTIVITY | UNIVERSITE GRENOBLE ALPES (FR) | 2024-08-02 | — | — | WO | claimed |
| CN-116217491-B | Benzimidazole single-functionalized column [5] arene N-heterocyclic carbene catalyst and preparation method and application thereof | 青岛科技大学 | 2024-05-14 | — | — | CN | claimed |
| CN-112955992-B | Dye sensitized photovoltaic cell | 环境光子学公司 | 2024-04-02 | — | — | CN | claimed |
| US-20240034737-A1 | Heterocyclic Derivatives as P2X7 Receptor Antagonists | BREYE THERAPEUTICS APS (DK) | 2024-02-01 | — | — | US | claimed |
| CN-117430738-A | Catalyst component for olefin polymerization, catalyst and application thereof | 中国石油化工股份有限公司 | 2024-01-23 | — | — | CN | claimed |
| WO-2023099689-A1 | METHOD FOR THE ELECTRO-OXIDATION OF A FURAN COMPOUND | IFP Energies Nouvelles (FR) | 2023-06-08 | — | — | WO | claimed |
| CN-116075510-A | 1H-benzo [ d ] imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis | 百时美施贵宝公司 | 2023-05-05 | — | — | CN | claimed |
| CN-116507617-B | 1- (2- (4-Cyclopropyl-1H-1, 2, 3-triazol-1-yl) acetyl) -4-hydroxypyrrolidine-2-carboxamide derivatives as VHL inhibitors | 基因泰克公司 | 2026-05-22 | — | — | CN | disclosed |
| CN-122029158-A | EGFR inhibitors | 缆图药品公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260115201-A1 | POTENTIAL THERAPEUTICS FOR FIBROSIS BY BLOCKING THE INCREASE OF A KEY ENZYME | TEXAS A & M UNIV SYS (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2022035917-A1 | SYNTHESIS OF FLUORINATED NUCLEOTIDES | MERCK SHARP & DOHME CORP. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-11241398-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2022-02-08 | — | — | US | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | HDAC6, HDAC9, HDAC1 | TDP1 1011/4885GRM5 1996/4885HTT 66/4885 |
| US-20260115201-A1 | POTENTIAL THERAPEUTICS FOR FIBROSIS BY BLOCKING THE INCREASE OF A KEY ENZYME | DDX3X, DDX39B, DDX1 | TDP1 1399/4885GRM5 4766/4885HTT 3518/4885 |
| US-20240034737-A1 | Heterocyclic Derivatives as P2X7 Receptor Antagonists | P2RX7, P2RX3, P2RX1 | TDP1 1868/4885GRM5 328/4885HTT 1934/4885 |
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | P2RX7, P2RX3, P2RX1 | TDP1 2215/4885GRM5 308/4885HTT 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.